Genus PLC
LSE:GNS
Genus PLC
LSE:GNS
Price:
1 820 GBX
3.76%
Market Closed
Updated:
May 30, 2024
Genus PLC
Operating Income
|
Genus PLC
Operating Income Peer Comparison
Comparables:
CNTA
EXAI
AUTL
BCYC
IMCR
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Operating Income
-£174.5m
|
CAGR 3-Years
-80%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$179.8m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
See Also
What is Genus PLC's Operating Income?
Operating Income
53m
GBP
53m
GBP
Based on the financial report for Dec 31, 2023, Genus PLC's Operating Income amounts to 53m GBP.
What is Genus PLC's Operating Income growth rate?
Operating Income CAGR 10Y
4%
4%
Over the last year, the Operating Income growth was -14%. The average annual Operating Income growth rates for Genus PLC have been 8% over the past three years , 4% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
